NCT07764796 Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
| NCT ID | NCT07764796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Breast Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-07-22 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2025-07-22 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial develops and studies how well mobile health (m-Health) patient navigation (PN) strategies work to improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya. Although highly curable, breast cancer kills thousands of women in developing countries yearly. Mammography (MMG) is used for the early detection of breast cancer by creating a picture of the breast using film or a computer. Despite the availability of MMG in all 47 counties in Kenya, screening remains low in eligible women. Early detection of breast cancer may also be improved through access to high quality clinical breast exams (CBE). However, primary care providers in Kenya face barriers to incorporating CBE into practice, including limited patient awareness of breast cancer screening. m-Health uses applications on mobile phones to deliver PN directly to the patients. The PN strategies in this study include digital platforms and tools to help with education, reminders, navigation, and motivation around breast cancer screening. This may improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya.
Eligibility Criteria
Inclusion Criteria: * AIM 1: All members of BREAKTHROUGH's Stakeholder Advisory Board (SAB) breast cancer working group * AIM 1: Participants (patients and health providers) from primary health care clinics in Nairobi County * AIM 1: Will include women (patients) aged over 35 years and speak either Kiswahili or English * AIM 1: Include women who: * Have never undergone MMG screening * Previously undergone MMG screening * Experienced breast abnormalities and have been referred for or undergone diagnostic investigations * Are currently undergoing or have received breast cancer treatment * AIM 1: Health care providers and breast screening facility staff (i.e. primary care clinic nurses, MMG clinic staff and technicians) will also be recruited * AIM 2: Will engage with a diverse group of local and national interagency stakeholders, Nairobi County health leadership, and health providers across different levels of the health system * AIM 3: Women aged 35 years and older who are able to provide informed consent who are attending the outpatient clinics for primary health care * AIM 4: Members of SAB breast cancer group, health facilities leadership (all health facility levels) Exclusion Criteria: * AIM 1: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study * AIM 2: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study * AIM 3: Women undergoing breast cancer treatment and women aged 70 years and above will be excluded * AIM 4: Members of SAB breast cancer group, and health facilities leadership who will be unwilling and unable to consent will be excluded
Contact & Investigator
Michael Chung
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT07764796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07764796 currently recruiting?
Yes, NCT07764796 is actively recruiting participants. Visit ClinicalTrials.gov or contact Emory University to inquire about joining.
Where is the NCT07764796 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT07764796 clinical trial?
NCT07764796 is sponsored by Emory University. The principal investigator is Michael Chung at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 800 participants.